医学
内科学
干细胞
造血干细胞移植
移植
肿瘤科
造血
急性白血病
白血病
免疫学
癌症研究
生物
遗传学
作者
Li Li,Ran Zhang,Weijie Cao,Zhilei Bian,Yang Qin,Rong Guo,Suping Zhang,Yingnan Peng,Dingming Wan,Wang Ma
标识
DOI:10.1080/10428194.2023.2252948
摘要
We retrospectively analyzed the outcomes of 136 consecutive patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center. Among them, 76 cases used hypomethylating agents (decitabine, n = 40; azacitidine, n = 36) as post-transplant maintenance therapy, whereas 60 contemporaneous patients did not adopt maintenance therapy. The 3-year incidences of relapse in two groups were 16.6% and 39.2% (p = .001). The 3-year OS and DFS in maintenance group were 84.0% and 78.6%, which were remarkably improved than in control group (60.0% and 58.0%) (p = .004, p = .011). Moreover, the 3-year relapse rates for patients receiving decitabine and azacitidine therapy were 8.5% and 25.0%, respectively (p = .019). Patients utilizing decitabine had more common possibility of grade 3-4 neutropenia than azacitidine (20.0% vs. 2.8%, p = .031). These results indicate that maintenance therapies using hypomethylating agents could reduce the risk of post-transplant recurrence, resulting into remarkable superior survival. Decitabine might lower relapse after allo-HSCT with somewhat more severe myelosuppression when being compared to azacitidine.
科研通智能强力驱动
Strongly Powered by AbleSci AI